These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 30690953)

  • 1. [New Systemic Therapies for Advanced Hepatocellular Carcinoma].
    Kim DY
    Korean J Gastroenterol; 2019 Jan; 73(1):10-15. PubMed ID: 30690953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.
    Lim H; Ramjeesingh R; Liu D; Tam VC; Knox JJ; Card PB; Meyers BM
    J Natl Cancer Inst; 2021 Feb; 113(2):123-136. PubMed ID: 32898239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond.
    Kudo M
    World J Gastroenterol; 2019 Feb; 25(7):789-807. PubMed ID: 30809080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma.
    Kudo M
    Int J Clin Oncol; 2022 Jul; 27(7):1110-1119. PubMed ID: 35527313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond.
    Feng MY; Chan LL; Chan SL
    Curr Oncol; 2022 Aug; 29(8):5489-5507. PubMed ID: 36005172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis.
    Chen J; Wang J; Xie F
    Medicine (Baltimore); 2021 Sep; 100(38):e27013. PubMed ID: 34559096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in Hepatocellular Carcinoma.
    Fulgenzi CAM; Talbot T; Murray SM; Silletta M; Vincenzi B; Cortellini A; Pinato DJ
    Curr Treat Options Oncol; 2021 Aug; 22(10):87. PubMed ID: 34424422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabozantinib: An evolving therapy for hepatocellular carcinoma.
    El-Khoueiry AB; Hanna DL; Llovet J; Kelley RK
    Cancer Treat Rev; 2021 Jul; 98():102221. PubMed ID: 34029957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.
    Gordan JD; Kennedy EB; Abou-Alfa GK; Beal E; Finn RS; Gade TP; Goff L; Gupta S; Guy J; Hoang HT; Iyer R; Jaiyesimi I; Jhawer M; Karippot A; Kaseb AO; Kelley RK; Kortmansky J; Leaf A; Remak WM; Sohal DPS; Taddei TH; Wilson Woods A; Yarchoan M; Rose MG
    J Clin Oncol; 2024 May; 42(15):1830-1850. PubMed ID: 38502889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic therapy for hepatocellular carcinoma: current status and future perspectives.
    Furuse J; Ueno M; Ikeda M
    Jpn J Clin Oncol; 2021 Aug; 51(9):1363-1371. PubMed ID: 34258616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma.
    Catalano M; Casadei-Gardini A; Vannini G; Campani C; Marra F; Mini E; Roviello G
    Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1353-1365. PubMed ID: 34289756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indonesian consensus on systemic therapies for hepatocellular carcinoma.
    Hasan I; Loho IM; Setiawan PB; Djumhana A; Purnomo HD; Siregar L; Gani RA; Sulaiman AS; Lesmana CRA
    Asia Pac J Clin Oncol; 2023 Feb; 19(1):263-274. PubMed ID: 35599455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging drugs for the treatment of hepatocellular carcinoma.
    Ayoub WS; Jones PD; Yang JD; Martin P
    Expert Opin Emerg Drugs; 2022 Jun; 27(2):141-149. PubMed ID: 35642526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging agents and regimens for hepatocellular carcinoma.
    Zhu XD; Sun HC
    J Hematol Oncol; 2019 Oct; 12(1):110. PubMed ID: 31655607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic considerations for angiogenesis inhibitors used to treat hepatocellular carcinoma: an overview.
    Borriello R; Cerrito L; Gasbarrini A; Ponziani FR
    Expert Opin Drug Metab Toxicol; 2023; 19(11):785-794. PubMed ID: 37847538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma.
    Su GL; Altayar O; O'Shea R; Shah R; Estfan B; Wenzell C; Sultan S; Falck-Ytter Y
    Gastroenterology; 2022 Mar; 162(3):920-934. PubMed ID: 35210014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis.
    Hiraoka A; Kumada T; Kariyama K; Takaguchi K; Atsukawa M; Itobayashi E; Tsuji K; Tajiri K; Hirooka M; Shimada N; Shibata H; Ishikawa T; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Itokawa N; Imai M; Joko K; Hiasa Y; Michitaka K;
    Cancer Med; 2019 Jan; 8(1):137-146. PubMed ID: 30575325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
    Chen Y; Hu H; Yuan X; Fan X; Zhang C
    Front Immunol; 2022; 13():896752. PubMed ID: 35757756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives.
    Trojan J
    Drugs; 2020 Aug; 80(12):1203-1210. PubMed ID: 32671719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paradigm shift in the treatment options of hepatocellular carcinoma.
    Su TH; Hsu SJ; Kao JH
    Liver Int; 2022 Aug; 42(9):2067-2079. PubMed ID: 34515412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.